Peer Review: Plotting US moves, Zealand Pharma poaches Alnylam's Emmanuel Dulac as new CEO
Concluding a four-month search for Britt Meelby Jensen’s replacement, Zealand Pharma has wooed top Alnylam exec Emmanuel Dulac to take the helm as its new CEO.
Dulac’s most recent role was chief commercial officer at Alnylam, where he was brought in to build a global commercial infrastructure in two years before the biotech notched a long-awaited approval for its groundbreaking RNAi medicine.
That job took him to Basel, Switzerland, with frequent trips to the Boston area. Adding that to his previous stints at Novartis and Shire as well as board seat at Proteostasis, Dulac brings years of experience working in both Europe and North America.
All that will come in handy as Copenhagen-based Zealand puts a foot down in the US. A Nasdaq biotech class of 2017, Zealand has a pipeline of peptide-based medicines that it’s pushing in orphan or rare indications.
More Peer Review
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 82,100+ biopharma pros reading Endpoints daily — and it's free.